Trichomonas vaginalis (TV) is the most common curable STI in the United states. Over 3.7 million people in the United States have TV, which is a higher prevalence than chlamydia and gonorrhea infections combined. The CDC recommends testing women for TV infection if they are symptomatic or at increased risk of infection. The CDC and ACOG also recommend the use of a highly sensitive and specific test, such as the Aptima® Trichomonas vaginalis assay.
The Aptima Trichomonas vaginalis assay is an rRNA-based NAAT that provides up to 100% sensitivity in detecting TV for both symptomatic and asymptomatic patients. This assay overcomes challenges associated with traditional, less sensitive methodologies because it can detect a fraction of one organism, whereas wet mount requires at least 10,000 motile organisms/mL to visualize.